NESS ZIONA, Israel--(BUSINESS WIRE)--Kadimastem Ltd. (TASE:KDST), focusing on the development and industrial commercialization of products based on human embryonic stem cells, announced today the closing of its initial public offering on the Tel Aviv Stock Exchange. The tender, which included 3.1 million shares and 2 option series, recorded demands in the scope of approximately 5.5 million USD. The tender price closed at 1.81 USD per share.
The first option series is for a period of two years from the date of the offering. The additional series is for a period of four years from the date of the offering.
The company announced that the capital raised will be used to expand its current activities.
Yossi ben Yossef, Kadimastem’s Co-Founder and CEO, stated: “We are happy with the results of the offering that, more than anything, reflect the investors’ confidence in the company’s unique capabilities. This is the first IPO in the Tel Aviv Stock Exchange in 18 months. I would like to thank our investors for their participation; we view them as critical to our future success.”
Rosario Underwriting Services acted as sole book-running manager for the offering. Discount Underwriting & Issuing LTD and Menora Mivtachim Underwriters & Management Ltd acted as co-managers for the offering.
The attorneys accompanying the offering on behalf of the Gornitzky & Co. Law Firm: Adv. Sharon Werker-Sagi and Adv. Etai Mashiach.
About Kadimastem
Kadimastem is a biotechnology company focusing on the development and
industrial commercialization of products based on human pluripotent stem
cells. Kadimastem’s technology in embryonic stem cells serves for the
production of unique human cells and tissue for two main types of
medical applications:
(1) A drug screening platform, which
uses stem cell-derived cells and tissues in an in vitro setting for the
discovery of new treatments for neurological diseases and diabetes.
(2)
Regenerative medicine, which corrects and renews tissues and organs
damaged from diseases such as transplant of insulin-secreting pancreatic
cells to treat insulin-dependent diabetes. Kadimastem develops these
innovative technologies in its advanced facilities located in the
Weizmann Science Park in Ness Ziona, Israel. To find out more please
visit Kadimastem’s website – www.kadimastem.com.
